New study of FDA cites the flaws be­hind rapid-fire can­cer drug OKs

Over the past few years the FDA’s on­col­o­gy group un­der Richard Paz­dur has tru­ly rev­o­lu­tion­ized the way can­cer drugs are de­vel­oped and re­viewed for mar­ket­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER